NNMT (E6N2Z) Rabbit XP^® mAb recognizes endogenous levels of total NNMT protein.

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro109 of human NNMT protein.

Nicotinamide N-methyltransferase (NNMT) is a metabolic enzyme expressed primarily in liver and adipose tissue. It catalyzes the transfer of a methyl group from S-Adenosyl-methionine (SAM) to nicotinamide, yielding 1-methylnicotinamide (MNAM) and S-Adenosyl-L-homocysteine (SAH) (1). This N-methylation enzymatic activity plays an important role in the biotransformation of drugs and xenobiotics, and also contributes to the metabolism of vitamin B3 (2). Knockdown of NNMT was shown to increase both SAM and NAD⁺ levels in white adipose tissue of high-fat diet-fed mice, resulting in increased energy expenditure and protection against diet-induced obesity (3). In contrast, increased liver NNMT expression in humans and mice correlated with an improved metabolic profile, through MNAM-mediated SIRT1 protein stabilization (4). In cancer cells, overexpression of NNMT resulted in excess consumption of methyl units from SAM, leading to histone hypomethylation that substantially altered the epigenetic landscape (5). These and other research studies have suggested that NNMT expression may have utility as a diagnostic and prognostic biomarker in cancer (6-8).